CRISPR Regulation
By Marcy Darnovsky,
ISSUES in Science and Technology
| 06. 05. 2019
As the debate about heritable genome editing unfolds, divergent perspectives are coming more clearly into view. Those who see it as offering little or no benefit while posing unacceptable societal risks support either the currently prevailing policies that ban it outright, or a moratorium that leaves the option of prohibition on the table. Enthusiasts, in contrast, speak of a “responsible path forward.” They dismiss the need for anything called a moratorium, and backpedal on the commitment to broad societal consensus made at the first International Summit on Human Gene Editing, in 2015.
There is one point of agreement: nearly everyone says they favor public engagement in the decision. But as suggested by the contributions to the Spring 2019 edition of Issues, there are important differences over just what kind of public engagement and deliberative process each has in mind.
The Center for Genetics and Society, a public interest and social justice organization, has long pressed the case for prohibiting human germline modification. We are confident that a meaningful deliberative process will conclude that this use of powerful genetic tools has...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...